FREMONT, Calif.--(BUSINESS WIRE)--FlowMedica, Inc., a medical device company pioneering Targeted Renal Therapy (TRT®), today announced that it has met its objective of enrolling 500 patients in the Be-RITE Registry. This is the first TRT registry data set that contains a significant number of patients with renal insufficiency who are at high risk for contrast induced nephropathy (CIN).
